{"cmr":"ca-cm-kg/TSX/EPRX","since":null,"total":13,"cursor":0,"limit":50,"next_cursor":null,"events":[{"cmr":"ca-cm-kg/TSX/EPRX","date":"2026-10-22","event_type":"newswire_release","title":"Eupraxia Pharmaceuticals to Participate at Upcoming","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/10/22/3386361/0/en/eupraxia-pharmaceuticals-to-participate-at-upcoming-conferences-and-host-a-virtual-analyst-day.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"HES-WnsQk4_v9TiGNqkM-i8Fu8QTtMdeBKAQnEzKCbbHpjWayWVLnYEdYXLFFn4q_wU_mPVBZw_qTvVSJMnLDQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ca-cm-kg/TSX/EPRX","date":"2026-10-15","event_type":"newswire_release","title":"Eupraxia Pharmaceuticals Reaches its Enrollment Target for","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/10/15/3381553/0/en/eupraxia-pharmaceuticals-reaches-its-enrollment-target-for-the-resolve-trial-investigating-ep-104gi-for-the-treatment-of-eosinophilic-esophagitis.html","read_by":"Tavily search (wire domains) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"8FAFVP-kbTF0pbzyzhWz1CBz6b412ISE-WtMiLzkyenQFZJTe0khOO_OdMa5ElvmENycvwDkujsw0MYAE7VFCw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ca-cm-kg/TSX/EPRX","date":"2026-10-09","event_type":"newswire_release","title":"Eupraxia Pharmaceuticals to Present at Upcoming American","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/10/09/3378041/0/en/eupraxia-pharmaceuticals-to-present-at-upcoming-american-college-of-gastroenterology-acg-and-united-european-gastroenterology-ueg-medical-conferences.html","read_by":"Tavily search (wire domains) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"NHAp8C_fuE3ZzK-tA6_GPvp9UwhgnxlnradbJ5vXwN8X2ZMXFckfxtfvHGFvgvRVEniRm4yGQ6qHBIFC-aMqAA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ca-cm-kg/TSX/EPRX","date":"2026-10-09","event_type":"newswire_release","title":"Eupraxia Pharmaceuticals to Present at Upcoming American","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/fr/news-release/2026/10/09/3378041/0/en/eupraxia-pharmaceuticals-to-present-at-upcoming-american-college-of-gastroenterology-acg-and-united-european-gastroenterology-ueg-medical-conferences.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"CZcqaCUQD-KdqRQOfY7NbDMaGvkuKEnuAIO2b91OI37McZmp_-OUbYXlEcAa6fGb0WaKWuWCMEZPtJ4ftoFEBA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ca-cm-kg/TSX/EPRX","date":"2026-09-30","event_type":"newswire_release","title":"Eupraxia Pharmaceuticals Reports 52-Week Data from the","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/09/30/3371804/0/en/eupraxia-pharmaceuticals-reports-52-week-data-from-the-highest-dose-cohort-of-ep-104gi-in-its-ongoing-phase-1b-2a-resolve-trial-for-the-treatment-of-eosinophilic-esophagitis.html","read_by":"Tavily search (wire domains) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"oXmsWVz3xeYalgkHXMzPCaddmpz909nwpklQbhZ1-V_W58EqIPcCweDji1Sl1gg4Ue1UmAhTNJSYVHphWyVEBQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ca-cm-kg/TSX/EPRX","date":"2026-04-22","event_type":"newswire_release","title":"Eupraxia Pharmaceuticals to Present at Digestive Disease","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/04/22/3278788/0/en/Eupraxia-Pharmaceuticals-to-Present-at-Digestive-Disease-Week-Annual-Meeting.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"XUgwwhVyqZsAbPNd-dz2eZX5Wmt1yfGRFPQBBPcv2mI0LK55-MPHtvG7LIMSSU3BBAHAZnwc4By9dyGvo4T1Ag","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ca-cm-kg/TSX/EPRX","date":"2026-04-22","event_type":"newswire_release","title":"Eupraxia Pharmaceuticals to Present at Digestive Disease","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/fr/news-release/2026/04/22/3278788/0/en/eupraxia-pharmaceuticals-to-present-at-digestive-disease-week-annual-meeting.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"2NeqyYOB_ACmCugu5cILA7PWVjPmr9fAbkYCSMnvGCi40-0HrYpxoFyizIYQ5TvDrOESOK2VzT29JfOCjv5oDg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ca-cm-kg/TSX/EPRX","date":"2026-04-22","event_type":"newswire_release","title":"Eupraxia Pharmaceuticals to Present at Digestive Disease","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/de/news-release/2026/04/22/3278788/0/en/eupraxia-pharmaceuticals-to-present-at-digestive-disease-week-annual-meeting.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"BMG87OS7FNNqLZm9SUNgdPPaEjg1qsLIbBGHPhG1XgPJ4cmiDcr4vkpFetPfYPeE0GN1kwuUOnjwoUMDaGqQBw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ca-cm-kg/TSX/EPRX","date":"2026-04-21","event_type":"newswire_release","title":"Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/04/21/3277764/0/en/Eupraxia-Pharmaceuticals-Reports-Positive-Nine-Month-Tissue-Health-and-Symptom-Data-from-the-Highest-Dose-Cohort-in-its-Ongoing-Phase-1b-2a-RESOLVE-Trial-in-Eosinophilic-Esophagiti.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"62_Oho84g9ZTmXPvcPLdDMuMoM5nL9nCdoQgJbCTmKpXghruQCP1SSCbitPqM_CmfbaFAOKf9UWpLiWDfGD-Dw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ca-cm-kg/TSX/EPRX","date":"2026-04-13","event_type":"newswire_release","title":"Eupraxia Pharmaceuticals to Present at Upcoming Investor","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/fr/news-release/2026/04/13/3272444/0/en/eupraxia-pharmaceuticals-to-present-at-upcoming-investor-conferences.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"dK-8te0mEuO-XFMZ-6KtE0LwKz2WHe4-zTnAMMGnmAa3FMqd23qMZnyjaQaXfj_1shXfwyjrLMoo4iUfn0gYBQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ca-cm-kg/TSX/EPRX","date":"2026-04-13","event_type":"newswire_release","title":"Eupraxia Pharmaceuticals to Present at Upcoming Investor","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/de/news-release/2026/04/13/3272444/0/en/eupraxia-pharmaceuticals-to-present-at-upcoming-investor-conferences.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"uwiUw8lucIQf9fJmuRdbhwFrZ8j1h301JSZer3WUYkvefnEUGh6-ckcHz9Cq3DBWldOk5-AUCQ-YSDZvUauzCw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ca-cm-kg/TSX/EPRX","date":"2026-04-13","event_type":"newswire_release","title":"Eupraxia Pharmaceuticals to Present at Upcoming Investor","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/04/13/3272444/0/en/Eupraxia-Pharmaceuticals-to-Present-at-Upcoming-Investor-Conferences.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"ZFOyoUtJq-cPrxOKqIRqX40yyys3THKWVh-HRFy-7R1HL2rJpVXYda_VRtu6EnTGnrQp_cEFDr8BiDugu-gGBw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ca-cm-kg/TSX/EPRX","date":"2026-03-17","event_type":"newswire_release","title":"Eupraxia Pharmaceuticals Reports Six-Month Symptom Data","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/03/17/3257002/0/en/Eupraxia-Pharmaceuticals-Reports-Six-Month-Symptom-Data-from-the-Highest-Dose-Cohort-in-its-Ongoing-Phase-1b-2a-RESOLVE-Trial-in-Eosinophilic-Esophagitis.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"UJrJVWFEWyNrj9Y8wb3Tsn6NtldOQO_1SzxIWmLOSu0bmBOek9sYowgVUGMEVfqmKjaqs81utznr1ASIO_XvCg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}}],"events_signed":"allooloo-cmr-2026-10"}